Regorafinib Plus Avelumab Provides Long-Term Benefit in Some

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors.

Related Keywords

Spain , Madrid , France , Institut Bergoni , , Sophie Cousin , Merck Serono , Gueganj P ,